Conference call scheduled for 9:00 AM
ET
REHOVOT, Israel, Aug. 1, 2023
/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN)(TASE: EVGN), a
leading computational biology company targeting to revolutionize
life-science product discovery and development across multiple
market segments, announced today that it will release its financial
results for the second quarter of 2023, on Thursday, August 17, 2023.
Later that day, Company management will host a conference call
to discuss the results at 9:00 AM Eastern
Time (4:00 PM Israel
time).
To join the conference call, please use the following numbers:
+1-888-281-1167 toll-free from the United
States or +972-3-918-0609 internationally. You can also find
access details for the call at
https://evogene.com/investor-relations/presentations-and-webcasts/
A replay of the conference call will be available approximately
two hours following the completion of the call. To access the
replay, please dial +1-888-326-9310 toll-free from the United States or +972-3-925-5901
internationally. The telephone replay will be accessible for three
days, but an archive of the webcast will be available from the
webcast link for the following twelve months.
About Evogene:
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational
biology company leveraging big data and artificial
intelligence, aiming to revolutionize the development of
life-science-based products by utilizing cutting-edge technologies
to increase the probability of success while reducing development
time and cost.
Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI. Each tech-engine is
focused on the discovery and development of products based on one
of the following core components: microbes (MicroBoost AI),
small molecules (ChemPass AI), and genetic elements
(GeneRator AI).
Evogene uses its tech-engines to develop products through
strategic partnerships and collaborations, and its five
subsidiaries including:
1. Biomica Ltd.
(www.biomicamed.com) developing and advancing novel
microbiome-based therapeutics to treat human disorders powered
by MicroBoost AI;
2. Lavie Bio
Ltd. (www.lavie-bio.com) - developing and
commercially advancing, microbiome based ag-biologicals powered by
MicroBoost AI;
3. AgPlenus Ltd. (www.agplenus.com) -developing
next generation ag chemicals for effective and sustainable crop
protection powered by ChemPass AI;
4. Canonic
Ltd. (www.canonicbio.com) – developing medical
cannabis products based on decoding plant genetics for optimized
therapeutic effect powered by GeneRator AI;
and
5. Casterra Ag Ltd. (www.casterra.co)–
developing and marketing superior castor seed varieties producing
high yield and high-grade oil content, on an industrial scale for
the biofuel and other industries powered by GeneRator
AI.
For more information, please visit: www.evogene.com.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo -
https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-schedules-second-quarter-2023-financial-results-release--conference-call-for-august-17-2023-301890215.html
SOURCE Evogene